Followers | 540 |
Posts | 76982 |
Boards Moderated | 3 |
Alias Born | 02/24/2010 |
![](https://investorshub.advfn.com/uicon/191143.png?cb=1556275054)
Friday, February 09, 2024 10:29:31 AM
Recent CVKD News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/12/2024 08:10:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/11/2024 09:27:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/11/2024 09:25:39 PM
- Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients • PR Newswire (US) • 06/03/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/29/2024 09:27:54 PM
- Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • PR Newswire (US) • 05/23/2024 01:00:00 PM
- Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update • PR Newswire (US) • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 10:23:10 AM
- Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024 • PR Newswire (US) • 04/11/2024 08:30:00 PM
- Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts • PR Newswire (US) • 04/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:15:09 PM
- Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update • PR Newswire (US) • 03/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:24:44 PM
- Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference • PR Newswire (US) • 02/26/2024 02:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/15/2024 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:49:23 PM
- Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial • PR Newswire (US) • 02/08/2024 02:00:00 PM
- Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions • PR Newswire (US) • 01/31/2024 02:00:00 PM
- Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 • PR Newswire (US) • 01/24/2024 02:00:00 PM
- Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference • PR Newswire (US) • 01/04/2024 02:00:00 PM
- Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target • PR Newswire (US) • 12/19/2023 02:00:00 PM
- Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization • PR Newswire (US) • 12/12/2023 02:00:00 PM
- Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023 • PR Newswire (US) • 11/30/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:15:30 PM
- Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update • PR Newswire (US) • 11/09/2023 02:00:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM